PAH combination therapy moves to first-line

Pulmonary arterial hypertension management has shifted to upfront combination therapy as the default for higher-risk patients. The sequential single-agent escalation paradigm of a decade ago is being replaced by triple-class or activin-modulator-included combinations from the start. The implementation question is whether community pulmonology adopts the more aggressive paradigm or refers earlier to PAH centres.